(Q38466180)

3 September 2017

Non-bacterial infections in Asian patients treated with alemtuzumab: a retrospective study of the Asian Lymphoma Study Group (English)

1 reference

3 September 2017

Surapol Issaragrisil

7

0 references

Jin Seok Kim

object named as

Jin Seok Kim

4

0 references

Ann-Lii Cheng

object named as

Ann-Lii Cheng

13

0 references

author name string

Seok Jin Kim

1

1 reference

3 September 2017

Joon Ho Moon

2

1 reference

3 September 2017

Hawk Kim

3

1 reference

3 September 2017

Yu Yan Hwang

5

1 reference

3 September 2017

Tanin Intragumtornchai

6

1 reference

3 September 2017

Jae Yong Kwak

8

1 reference

3 September 2017

Je Jung Lee

9

1 reference

3 September 2017

Jong Ho Won

10

1 reference

3 September 2017

Arry Harryanto Reksodiputro

11

1 reference

3 September 2017

Soon Thye Lim

12

1 reference

3 September 2017

Won Seog Kim

14

1 reference

3 September 2017

Yok Lam Kwong

15

1 reference

3 September 2017

1 March 2012

1 reference

3 September 2017

1 reference

3 September 2017

53

1 reference

3 September 2017

1515-1524

1 reference

3 September 2017

8

1 reference

Expression of CD52 in peripheral T-cell lymphoma

3 September 2017

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.659735

Immunohistochemical analysis of CDw52 antigen expression in non-Hodgkin's lymphomas

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.659735

Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.659735

Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.659735

Alemtuzumab (Campath-1H) and CHOP chemotherapy as first-line treatment of peripheral T-cell lymphoma: results of a GITIL (Gruppo Italiano Terapie Innovative nei Linfomi) prospective multicenter trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.659735

A pilot study of alemtuzumab (anti-CD52 monoclonal antibody) therapy for patients with relapsed or chemotherapy-refractory peripheral T-cell lymphomas

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.659735

Alemtuzumab and DHAP (A-DHAP) is effective for relapsed peripheral T-cell lymphoma, unspecified: interim results of a phase II prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.659735

Outcomes after alemtuzumab-containing reduced-intensity allogeneic transplantation regimen for relapsed and refractory non-Hodgkin lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.659735

Alemtuzumab for the treatment of steroid-refractory acute graft-versus-host disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.659735

Alemtuzumab-induced resolution of refractory cutaneous chronic graft-versus-host disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.659735

Cellular immune reconstitution after subcutaneous alemtuzumab (anti-CD52 monoclonal antibody, CAMPATH-1H) treatment as first-line therapy for B-cell chronic lymphocytic leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.659735

Early prediction of outcome and response to alemtuzumab therapy in chronic lymphocytic leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.659735

Spectrum of infection, risk and recommendations for prophylaxis and screening among patients with lymphoproliferative disorders treated with alemtuzumab*.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.659735

Results of a phase I/II British Society of Bone Marrow Transplantation study on PCR-based pre-emptive therapy with valganciclovir or ganciclovir for active CMV infection following alemtuzumab-based reduced intensity allogeneic stem cell transplantat

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.659735

Monitoring for cytomegalovirus and Epstein-Barr virus infection in chronic lymphocytic leukemia patients receiving i.v. fludarabine-cyclophosphamide combination and alemtuzumab as consolidation therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.659735

The Japanese experience with biologic therapies for rheumatoid arthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.659735

Reactivation of hepatitis B virus following systemic chemotherapy for malignant lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.659735

Impact of alemtuzumab as conditioning regimen component on transplantation outcomes in case of CMV-seropositive recipients and donors

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.659735

Clinical features of late cytomegalovirus infection after hematopoietic stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.659735

A pilot dose-escalating study of alemtuzumab plus cyclosporine for patients with bone marrow failure syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.659735

Dose modification of alemtuzumab in combination with dexamethasone, cytarabine, and cisplatin in patients with relapsed or refractory peripheral T-cell lymphoma: analysis of efficacy and toxicity.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.659735

Fatal adenovirus infection during alemtuzumab (anti-CD52 monoclonal antibody) treatment of a patient with fludarabine-refractory B-cell chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.659735

Epstein-Barr virus-positive B-cell lymphoproliferative disorders arising in immunodeficient patients previously treated with fludarabine for low-grade B-cell neoplasms

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.659735

Alemtuzumab as treatment for residual disease after chemotherapy in patients with chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.659735

Management of infections in patients with chronic lymphocytic leukemia treated with alemtuzumab

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.659735

Antiviral prophylaxis in patients with haematological malignancies and solid tumours: Guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society for Hematology and Oncology (DGHO).

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.659735

Lamivudine for the prevention of hepatitis B virus reactivation in hepatitis B s-antigen seropositive cancer patients undergoing cytotoxic chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.659735

Hepatitis B virus reactivation and alemtuzumab therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.659735

Occult hepatitis B virus infection: a hidden menace?

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.659735

Persistent hepatitis B virus infection in subjects without hepatitis B surface antigen: clinically significant or purely "occult"?

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.659735

Prevalence of occult HBV infection among subjects with normal serum ALT levels in Korea.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.659735

High incidence of tuberculosis after alemtuzumab treatment in Hong Kong Chinese patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.659735

10.3109/10428194.2012.659735

21 January 2018

Identifiers

DOI

1 reference

3 September 2017

1 reference